|
|
 |
|
Viewing report
|
|
|
|
The Cancer Market Outlook to 2010
Business Insights, Nov 2005
The cancer market has undergone a high degree of innovation led change over the previous five years, which has created strong opportunities for a range of established and emerging biotechnology and pharmaceutical companies.
The new report 'The Cancer Market Outlook to 2010' provides detailed analysis on 9 key indications in the cancer market, identifying growth brands, leading companies and epidemiology and product sales forecasts over the period 2005-2010. The 6-year forecasts detailed in this report will enable you to evaluate changes in the competitive positions of leading companies in the cancer market and ensure your R&D pipeline is aligned with future market opportunity to sustain revenue growth.
This report will enable you to benchmark the strategies behind the market-leading products of today and identify which products will be best positioned for growth over the period 2005-2010.
Key statistics and analysis detailed in this report:
- Company analysis and market share of the top players in the cancer market including:
- Roche, Johnson & Johnson, AstraZeneca, Novartis, BMS and Sanofi-Aventis
- Epidemiological analysis and forecasts in 9 key indications in the cancer market including: leukaemia, lymphoma, lung, breast, pancreatic, colorectal, and prostate cancer
- Detailed analysis and sales forecasts of high potential products in the pipelines of the major players
Maximize future market opportunity with the help of this report.
The answers to your questions
- What will be the major growth indications in the cancer market over the period 2005-2010?
- Which companies were the winners and losers in the cancer market in 2004?
- How have recent major launches from Novartis, Roche, Lilly and Bristol-Myers Squibb performed?
- Which products will be impacted by generic competitors over the period 2005-2010?
- Which pipeline products will be the growth drivers of the future and why?
- What will the competitive landscape in leukaemia, lymphoma, lung, breast, pancreatic, colorectal, and prostate cancer look like in 2010?
Why buy this report?
- Save time and money in research with the report's coverage of the 9 largest indications in the cancer market, the 7 largest geographic pharmaceutical markets and the 8 largest companies active in the cancer market today.
- Understand now how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in cancer marketplace.
- Discover which cancer indications have the greatest potential to provide franchise growth, and how the pharmaceutical industry is attempting to exploit these opportunities.
- Compare the franchises of key players in the cancer market across major indications, and understand how the market share of leading companies will change over the next 6 years.
- Use head-to-head comparisons of the cancer pipelines of the leading players to understand which companies will be competing in the key cancer indications over the next 6 years.
|
|
|
|
